Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

• DOI: 10.1200/jco.2023.41.16_suppl.10010
• Publication Date: 2023-06-04T16:26:49Z
• Authors: Emily Jones; Arlene Naranjo; Lena E. Winestone; Puja J Umaretiya; Rahela Aziz-Bose; Lenka Anne Skaidr...; Emily Gustava Gre...; Steven G. DuBois; Rochelle Bagatell; Kira Bona
• Keywords: Cog

10010 Background: Children who are Black, Hispanic or of proxied low socioeconomic status experience inferior survival outcomes despite receipt uniform treatment on Children’s Oncology Group (COG) trials. Investigation mechanisms underlying these disparities and evaluation interventions to address them has been limited by inadequate data. Prior COG trials have collected child race, ethnicity, insurance zip code—non-modifiable data elements that prone misclassification bias—as proxies for exposure adverse social determinants health (SDOH). Collection parent-reported SDOH provides key information not previously assessed in trials, including modifiable exposures such as household material hardship (HMH): food, housing, utility transportation insecurity. We report the preliminary feasibility acceptability first trial prospectively embed collection. Methods: ANBL1531 (NCT03126916), current frontline, groupwide patients with high-risk neuroblastoma, was amended September 2019 include an opt-in, correlative aim evaluate SDOH. Parents < 18 years could opt-in during initial consent complete a brief, single-timepoint survey at their enrolling site Induction Cycle 1. Survey domains included demographics, HMH, income, support. Paper/pencil surveys available English, Spanish French were self-completed read-aloud personnel be administered any language interpreter. Surveys submitted central study team cleaning entry into electronic database. Results: As December 31, 2022, 360/413 eligible participants opted-in embedded across 101 sites (87.2% rate). Among participants, 316 (87.8%) completed median 11 days post-enrollment. Four (1.1%) parents declined completion (3 withdrew consent). Reasons non-completed included: still pending within protocol-specified window (n = 10), institutional COVID-19 restrictions 6), scheduling issues patient came off protocol 5) unknown 13). Data missingness primary interest, 0.8%. Spanish, French, Vietnamese, Arabic, Mandarin Tamil. Conclusions: optional, component is feasible acceptable, demonstrated remarkable willingness participate infrequency missing Incorporation this approach future National Clinical Trials Network essential inform impactful equity research, development targeted outcome disparities.